NL Life Sciences BV 4
4 · Natur International Corp. · Filed Aug 13, 2019
Insider Transaction Report
Form 4
NL Life Sciences BV
10% Owner
Transactions
- Conversion
Common Stock, Par Value $0.001
2019-06-27+61,848,000→ 82,450,133 total(indirect: See Footnote) - Conversion
Series B Convertible Preferred Stock, par value $0.001
2019-06-27−61,848→ 0 total(indirect: See Footnote)→ Common Stock
Footnotes (2)
- [F1]These securities are held by NL Life Sciences BV. Mr. Rhys Tombling is the sole director of NL Life Sciences BV and is deemed to have voting and dispositive power over the securities held by NL Life Sciences BV. Mr. Tombling disclaims beneficial ownership of all securities held by NL Life Sciences BV.
- [F2]Each share of Series B Convertible Preferred Stock was automatically convertible into 1,000 shares of common stock. The conversion took place upon the issuer increasing its authorized common stock on June 27, 2019, with no action by the reporting person.